717109-27-8

Basic information

• Product Name: ethyl 3-iodo-5-methoxybenzoate
• Synonyms: ethyl 3-iodo-5-methoxybenzoate;3-Iodo-5-methoxybenzoic acid methyl ester;methyl 3-iodo-5-methoxybenzoate
• CAS NO: 717109-27-8
• Molecular Formula: C₉H₉IO₃
• Molecular Weight: 306.1
• Mol File: 717109-27-8.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.684
• Refractive Index: 1.569
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ethyl 3-iodo-5-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-iodo-5-methoxybenzoate(717109-27-8)
• EPA Substance Registry System: ethyl 3-iodo-5-methoxybenzoate(717109-27-8)

Safety Data

• Hazardous Substances Data: 717109-27-8(Hazardous Substances Data)

Usage

General Description

Ethyl 3-Iodo-5-Methoxybenzoate is a chemical compound with the molecular formula C10H11IO3. It is an ester formed from the condensation of 3-iodo-5-methoxybenzoic acid and ethanol. Ethyl 3-Iodo-5-Methoxybenzoate is commonly used in organic synthesis as a reagent for the preparation of various pharmaceuticals, agrochemicals, and other fine chemicals. It is also utilized in the study of structure-activity relationships in drug design. Ethyl 3-Iodo-5-Methoxybenzoate is a white to off-white crystalline solid with a molecular weight of 304.09 g/mol and is sparingly soluble in water but soluble in organic solvents. It is important to handle this compound with proper safety precautions as it is a potentially hazardous material.

InChI:InChI=1/C10H11IO3/c1-3-14-10(12)7-4-8(11)6-9(5-7)13-2/h4-6H,3H2,1-2H3

Upstream product

• 217314-47-1 methyl 3-amino-5-methoxybenzoate 
• 74165-74-5 3-amino-5-methoxybenzoic acid 

Downstream Products

• 74440-82-7 3-iodo-5-methoxybenzoic acid 

Relevant articles and documents

Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor

Monoacylglycerol lipase (MAGL) is the enzyme degrading the endocannabinoid 2-arachidonoylglycerol, and it is involved in several physiological and pathological processes. The therapeutic potential of MAGL is linked to several diseases, including cancer. The development of MAGL inhibitors has been greatly limited by the side effects associated with the prolonged MAGL inactivation. Importantly, it could be preferable to use reversible MAGL inhibitors in vivo, but nowadays only few reversible compounds have been developed. In the present study, structural optimization of a previously developed class of MAGL inhibitors led to the identification of compound 23, which proved to be a very potent reversible MAGL inhibitor (IC50 = 80 nM), selective for MAGL over the other main components of the endocannabinoid system, endowed of a promising antiproliferative activity in a series of cancer cell lines and able to block MAGL both in cell-based as well as in vivo assays.